Adam Spielman, Head of Health, Citi Global Insights with Jim Hollingshead, Chief Executive Officer, Insulet, discuss GLP-1s and their impact on Diabetes Care.
Key topics:
- In what ways are GLP-1s impacting Insulet’s business?
- How do diabetics who use GLP-1s behave differently from non-users?
- To what extent is Insulet changing its strategy because of GLP-1s?
- If GLP-1s do reduce obesity long term, what impact would there be?
